Kite

Gilead highlights Yescarta survival data in ASCO update

https://pharmaphorum.com/news/gilead-highlights-yescarta-survival-data-in-asco-update/

Gilead develops solid tumour cell therapy with Gadeta

https://pharmaphorum.com/news/gilead-develops-solid-tumour-cell-therapy-with-gadeta/

Kite expands manufacturing capacity for CAR-T therapies

https://pharmaphorum.com/news/kite-expands-manufacturing-capacity-for-car-t-therapies/

Kite and Sangamo come together in $3bn cancer gene editing alliance

https://pharmaphorum.com/views-analysis-oncology/kite-sangamo-come-together-3bn-cancer-gene-editing-alliance/

Cellectis CAR-T trials on hold after patient death

https://pharmaphorum.com/news/cellectis-car-t-trials-hold-patient-death/

Kite begins EU trial of CAR-T therapy

https://pharmaphorum.com/news/kite-eu-car-t-therapy/

Kite keeps pressure on Novartis with CAR-T filing

https://pharmaphorum.com/news/kite-keeps-pressure-novartis-car-t-filing/

Servier and Pfizer begin trials for off-the-shelf T-cell cancer therapy

https://pharmaphorum.com/news/servier-and-pfizer-car-t/

Orphan drugs will fuel pharma’s future – and a pricing pushback too

https://pharmaphorum.com/views-and-analysis/orphan-drugs-will-fuel-pharmas-future/

1 2

Close in 10 seconds

Pharmaphorum.com

Search